Summit Trail Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Summit Trail Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.33M	Buy	71,314 +16,548	+30%	+$965K	0.06%	189
2025 Q4	$2.95M	Sell	54,766 -6,469	-11%	-$311K	0.05%	243
2025 Q3	$2.76M	Sell	61,235 -322	-0.5%	-$15K	0.04%	282
2025 Q2	$2.85M	Buy	+61,557	New	+$3.02M	0.05%	196
2024 Q4	–	Sell	-49,473	Closed	-$2.56M	–	451
2024 Q3	$2.56M	Buy	49,473 +894	+2%	+$41.9K	0.06%	136
2024 Q2	$2.02M	Buy	48,579 +32,236	+197%	+$1.44M	0.05%	144
2024 Q1	$886K	Buy	16,343 +4,717	+41%	+$240K	0.02%	234
2023 Q4	$597K	Sell	11,626 -1,765	-13%	-$92.6K	0.02%	251
2023 Q3	$777K	Sell	13,391 -2,389	-15%	-$146K	0.03%	202
2023 Q2	$1.01M	Buy	15,780 +5,064	+47%	+$340K	0.04%	169
2023 Q1	$743K	Buy	10,716 +5,136	+92%	+$362K	0.03%	165
2022 Q4	$401K	Sell	5,580 -583	-9%	-$44K	0.02%	218
2022 Q3	$438K	Buy	6,163 +1,098	+22%	+$79.6K	0.02%	202
2022 Q2	$393K	Buy	5,065 +1,842	+57%	+$140K	0.02%	222
2022 Q1	$237K	Buy	+3,223	New	+$216K	0.02%	280
2020 Q4	–	Sell	-4,086	Closed	-$256K	–	203
2020 Q3	$256K	Buy	+4,086	New	+$246K	0.05%	175
2018 Q2	–	Sell	-7,710	Closed	-$279K	–	509
2018 Q1	$279K	Sell	7,710 -245	-3%	-$15.8K	0.05%	294
2017 Q4	$503K	Buy	+7,955	New	+$498K	0.06%	228

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Trail Advisors's BMY Position: Q1 2026 in Review

Summit Trail Advisors increased its Bristol-Myers Squibb (BMY) stake by 30% in Q1 2026, buying an estimated $965K and bringing the position to 71,314 shares worth $4.33M. The position accounts for 0.06% of the portfolio, ranked #189.

Summit Trail Advisors first reported a position in BMY in Q4 2017 and has held it in 18 quarters since. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Summit Trail Advisors held 71,314 shares of Bristol-Myers Squibb worth $4.33M as of Q1 2026.
Summit Trail Advisors bought 16,548 Bristol-Myers Squibb shares in Q1 2026, an estimated $965K.
Bristol-Myers Squibb made up 0.06% of Summit Trail Advisors's portfolio in Q1 2026, its #189 holding.
Summit Trail Advisors first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 18 quarters since.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.